Decibel Therapeutics Company
Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technology and our expertise in inner ear biology. We are leveraging our platform to advance our pipeline of preclinical gene therapy programs that are designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders.
Founded Date:
2015
Total Funding:
189.2M
Investor Type:
IPO
Employee Number:
51-100
Funding Status:
IPO
Number Of Exists:
51-100
Technology:
Other
Last Funding Type:
Series D
Investors Number:
16
Last Funding Date:
2020
Industry:
Biotechnology, Gene therapy, Medical Device, Therapeutics
Headquarters:
Cambridge, Massachusetts, United States
Estimated Revenue:
$10M to $50M